Status: Recruiting
Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients
To assess the efficacy of prophylactic treatment with deucrictibant extended release (XR) tablet versus placebo in preventing angioedema attacks, and to also assess the efficacy of deucrictibant soft capsules as on-demand treatment versus placebo in achieving angioedema symptom relief during acute attacks.
Participants needed: 10
Trial details
Phase: Phase 1, Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Institute for Asthma and AllergyUpdated: Jul 2, 2025Locations: 1
Eligibility criteria
Provision of written informed consent. [+7]
Any diagnosis of angioedema other than BK-AE-nC1INH. [+11]